Norwa Tissue Culture Laboratory

norwa.eu

The laboratory specialises in tissue culture multiplication of garden plants. It is a family run business established and successfully operating since 1984. We cooperate with top research institutions and have in in-depth knowledge of plants biology.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

ZS AND SEVEN BRIDGES COLLABORATE TO INNOVATE DRUG RESEARCH

ZS, Seven Bridges | May 07, 2021

news image

ZS and Seven Bridges disclosed a collaboration today that will merge ZS's experience in biomedical testing facilities and data science with Seven Bridges' technology platform, which enables multi-omics analytics through the translational and clinical continuum. The hybrid offers biopharmaceutical and biotechnology firms a one-stop-shop for multi-omics analysis innovation and scalability. ZS and Seven Bridges work together to help clients produce breakthrough science, promote drug develop...

Read More

Industry Outlook

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

news image

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More

Cell and Gene Therapy, Industrial Impact

CBM, STOIC BIO AND NUCLEUS BIOLOGICS ANNOUNCE STRATEGIC ALLIANCE

The Center for Breakthrough Medicines | March 13, 2023

news image

Nucleus Biologics and Stoic Bio have teamed up to form a supply agreement with the Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization that aims to accelerate the development and manufacture of advanced therapies. Under the agreement, Nucleus Biologics will become CBM's selected supplier of cell culture media and other biological solutions, ensuring a consistent supply of this critical material with tighter quality control measures. ...

Read More

Research

KINETA AND SAMSUNG BIOLOGICS ANNOUNCE ANTI-VISTA ANTIBODY IMMUNOTHERAPY DEVELOPMENT AND MANUFACTURING AGREEMENT

Samsung Biologics | July 21, 2021

news image

Kineta, Inc., a clinical-stage biotech firm developing novel immunotherapies in oncology, has signed a strategic partnership agreement with Samsung Biologics, one of the world's top contract development and manufacturing companies (CDMO). To support the IND filing for KVA12.1, Kineta's new anti-VISTA antibody under development to treat solid tumors, Samsung Biologics will offer end-through-end CDMO services ranging from cell line development to cell line development clinical drug substan...

Read More
news image

MedTech

ZS AND SEVEN BRIDGES COLLABORATE TO INNOVATE DRUG RESEARCH

ZS, Seven Bridges | May 07, 2021

ZS and Seven Bridges disclosed a collaboration today that will merge ZS's experience in biomedical testing facilities and data science with Seven Bridges' technology platform, which enables multi-omics analytics through the translational and clinical continuum. The hybrid offers biopharmaceutical and biotechnology firms a one-stop-shop for multi-omics analysis innovation and scalability. ZS and Seven Bridges work together to help clients produce breakthrough science, promote drug develop...

Read More
news image

Industry Outlook

XALUD THERAPEUTICS COMPLETES OVERSUBSCRIBED $30 MILLION SERIES C FINANCING

Xalud Therapeutics | August 25, 2021

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that it has raised $30 million in a Series C financing. “We are well positioned to continue advancing XT-150, our lead therapeutic candidate, through clinical development and further expand our platform” XT-150 is a locally injectable plasmid DNA gene therapy expressing IL-10v – a proprietary long-acting, mo...

Read More
news image

Cell and Gene Therapy, Industrial Impact

CBM, STOIC BIO AND NUCLEUS BIOLOGICS ANNOUNCE STRATEGIC ALLIANCE

The Center for Breakthrough Medicines | March 13, 2023

Nucleus Biologics and Stoic Bio have teamed up to form a supply agreement with the Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization that aims to accelerate the development and manufacture of advanced therapies. Under the agreement, Nucleus Biologics will become CBM's selected supplier of cell culture media and other biological solutions, ensuring a consistent supply of this critical material with tighter quality control measures. ...

Read More
news image

Research

KINETA AND SAMSUNG BIOLOGICS ANNOUNCE ANTI-VISTA ANTIBODY IMMUNOTHERAPY DEVELOPMENT AND MANUFACTURING AGREEMENT

Samsung Biologics | July 21, 2021

Kineta, Inc., a clinical-stage biotech firm developing novel immunotherapies in oncology, has signed a strategic partnership agreement with Samsung Biologics, one of the world's top contract development and manufacturing companies (CDMO). To support the IND filing for KVA12.1, Kineta's new anti-VISTA antibody under development to treat solid tumors, Samsung Biologics will offer end-through-end CDMO services ranging from cell line development to cell line development clinical drug substan...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us